The global inhaled antibiotics market is primarily driven by the increasing prevalence of respiratory tract infections such as cystic fibrosis, chronic obstructive pulmonary disease (COPD) and pneumonia. Inhaled antibiotics provide localized targeted therapy directly in the lungs, thereby reducing systemic side effects. The market comprises various product types including dry powder inhalers and nebulizers that efficiently deliver antibiotics for treating respiratory infections.
The global inhaled antibiotics market is primarily driven by the increasing prevalence of respiratory tract infections such as cystic fibrosis, chronic obstructive pulmonary disease (COPD) and pneumonia. Inhaled antibiotics provide localized targeted therapy directly in the lungs, thereby reducing systemic side effects. The market comprises various product types including dry powder inhalers and nebulizers that efficiently deliver antibiotics for treating respiratory infections.
